What the research shows
SELECT randomized 17,604 adults with overweight or obesity, established cardiovascular disease and no diabetes. Over a mean 39.8 months, cardiovascular death, nonfatal heart attack or nonfatal stroke occurred in 6.5% of the injectable semaglutide group and 8.0% of the placebo group. SELECT cardiovascular outcomes trial.
The U.S. Wegovy label identifies injectable solution and tablets. It describes the evidence, formulation and population for each indication. Wegovy prescribing information.
Documented formats
Wegovy is documented as an injectable solution and as tablets. SELECT studied an injectable formulation.
Testing and purity
Match the active ingredient, dosage form and label identifier to the specific product record. A report for a semaglutide raw material cannot establish the identity or performance of a finished tablet.
How to read a batch reportQuestions about Semaglutide
Who qualified for SELECT?
Participants were at least 45 years old and had preexisting cardiovascular disease. The findings directly address that population.
What does a composite outcome count?
SELECT counted the first occurrence of any one of three specified cardiovascular events. The combined rate does not give the individual rate for each event.